Abstract:Background: In the past two decades, a large-scale survey of hemoglobinopathies and thalassemia was carried out in mainland China, involving nearly one million people in 28 provinces. The incidences of hemoglobin (Hb) variants, α-thalassemia and β-thalassemia were 0.33%, 2.64% and 0.66%, respectively. The chemical structural analysis identified 67 Hb variants. Among them, 20 are new variants. The analysis of the α-globin gene organization in 111 HbH patients showed 76 cases (68.5%) were of the deletion type, 8 had Hb Constant Spring and the other cases were of non-deletion type. The results of the molecular characterization of more than 200 β-thalassemia alleles showed that the most common types of β-thalassemia mutations in China are CD 41/42 (−4 bp), IVS-II-nt.654 C→T, CD 17 A→T, CD 71/72 (+A) and −28 A→G. Methods: To explore the simple method for molecular diagnosis of β-thalassemia, multiplex allele-specific amplification (MAS-PCR) was used that could simultaneously detect the above five common types of β-thalassemia mutations. Results: Based on the molecular analysis of β-thalassemia intermedia, β-thalassemia homozygotes or compound heterozygotes combined with α-thalassemia, as well as the conjunctive abnormalities of β-thalassemia heterozygote with triplicated haplotype of α-globin genes, were the most common cause of thalassemia intermedia in China. We also used the RT-PCR quantitation method to show that the most common β-thalassemia allele, IVS-II-nt.654 C→T, still produced a small amount (about 15%) of normally spliced β-globin mRNA, therefore, causing β+-thalassemia. In clinical trials of hydroxyurea (HU) treatment for β-thalassemia patients, we found that HU may enhance the expression of the β-globin gene in some patients, leading to an alleviation of clinical symptoms. In the studies of the reversal of aberrant splicing of IVS-II-nt.654 C→T allele by the antisense approach, we constructed a mammalian expression vector that can produce an antisense RNA targeting against the aberrant splice sites of IVS-II-nt.654 C→T pre-mRNA. Conclusions: The results indicated that the antisense RNA produced from the vector could efficiently suppress the aberrant splicing pattern and restore the correct splicing pathway in vitro and in vivo, leading to the improvement of globin chain biosynthesis in thalassemia cells.

A single-base change at a splice site in a β0-thalassemic gene causes abnormal RNA splicing

A new mutation in IVS-1 of the human β globin gene causing β thalassemia due to abnormal splicing

Specific transcription and RNA splicing defects in five cloned β-thalassaemia genes

Splice Acceptor Mutation [HBB:c.93-2A > T] in a Patient with Hb S/β0-Thalassemia

Repair of Thalassemic Human Β-Globin Mrna in Cultured Erythroid Cells by Antisense RNA

RNA Transcripts of the Β‐thalassaemia Allele IVS‐2–654 C → T: a Small Amount of Normally Processed Β‐globin Mrna is Still Produced from the Mutant Gene

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

A novel Globin Gene Cluster Duplication, <SUP>380</SUP> Heterozygous <SUP>0</SUP>-Thal Variant, Leading to a Blood Transfusion-Dependent Phenotype

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Synonymous Variant at the Terminal Nucleotide in Exon 3 of F7 Causes Abnormal Splicing: A Case Report

Structure and in vitro transcription of human globin genes

Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

Editing Aberrant Splice Sites Efficiently Restores Β-Globin Expression in Β-Thalassemia

A Novel 165 Kb Duplication Involving the α-Globin Gene Cluster Is Identified by Low-Pass Whole Genome Sequencing in a Chinese Thalassemia Intermedia Patient

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia

Normal and mutant human β-globin pre-mRNAs are faithfully and efficiently spliced in vitro

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells